Who Paid My Doc
Ryan Larsen
General Practice Logan, UT Medical Doctor
NPI 1235224932 CMS profile 1308415
258 S Main St Ste 210, Logan, UT 84321
General payments
$821
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Ryan Larsen of Logan, UT is reported in the CMS Open Payments database as having received $821 across 38 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 77th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $255 | 2 | |
| 2021 | General | $20 | 1 | |
| 2020 | General | $124 | 10 | |
| 2019 | General | $422 | 25 |
Beside peers
- Ryan Larsen
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Ryan Larsen were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Ryan Larsen | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $422 | $107 | $37–$285 | $163 |
| 2020 | $124 | $75 | $25–$213 | $114 |
| 2021 | $20 | $93 | $30–$272 | $132 |
| 2022 | $0 | $103 | $36–$279 | $149 |
| 2023 | $255 | $106 | $34–$276 | $160 |
| 2024 | $0 | $114 | $39–$290 | $164 |
| 2025 | $0 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 53 drugsPart D claims
1,316
Drug cost
$68,162
Branded share of claims
15.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 41 | $17,361 | |
| Farxiga Dapagliflozin Propanediol | Brand | 20 | $8,397 | |
| Creon Lipase/Protease/Amylase | Brand | 13 | $6,762 | |
| Trintellix Vortioxetine Hydrobromide | Brand | 12 | $4,632 | |
| Potassium Chloride | Generic | 85 | $2,971 | |
| Famotidine | Generic | 54 | $2,457 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 25 | $2,152 | |
| Gabapentin | Generic | 22 | $1,614 | |
| Diclofenac Sodium | Generic | 36 | $1,524 | |
| Vancomycin Hcl | Generic | 40 | $1,508 |
The 10 drugs with the highest cost, of 53 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 7 billing codesPaid by Medicare
$8,031
Medicare patients
48
Services billed
72
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 73% | |
| Depression | 54% | |
| Arthritis | 54% | |
| Chronic kidney disease | 46% | |
| Heart failure | 44% | |
| Atrial fibrillation | 29% | |
| Alzheimer's or dementia | 29% | |
| Ischemic heart disease | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
38 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in Utah
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Utah
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.